Skip to content

Health Care Utilisation Among Survivors of Childhood Acute Lymphoblastic Leukaemia

Health Care Utilisation Following Childhood Acute Lymphoblastic Leukaemia: A Matched Cohort Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03985826
Enrollment
7348
Registered
2019-06-14
Start date
2019-09-01
Completion date
2019-11-30
Last updated
2020-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Brief summary

Improved understanding of the long-time healthcare utilisation of childhood cancer survivors is relevant as it can be seen as a proxy for the population's morbidity. The investigators will conduct a historic population-based matched cohort study using Danish nationwide registry data. Eligible children are children 1.0-17.9 years diagnosed with Acute lymphoblastic leukaemia (ALL) in Denmark from 1994 till 2016. The primary outcome is yearly contact rates to primary healthcare.

Detailed description

Acute lymphoblastic leukaemia (ALL) is the most frequent single form of cancer in children accounting for 40-45 new cases every year in Denmark. Over the past decades, advances in treatment have led to an increasing number of children who survive cancer and more than 80% of children with ALL now become long-term survivors. This means a growing population of childhood ALL survivors. In survivors, the cancer itself and treatment late-effects can lead to ongoing health care use. Register studies of long-term survivors of childhood cancer have shown an increased risk of hospitalisation compared to the general population. It is mentioned in many of the studies that contact rates could be underestimated when looking at hospital contacts only. The literature about non-hospital-based contacts with a doctor in childhood cancer survivors is scarce.

Interventions

OTHERDiagnosis of and treatment for Acute lymphoblastic leukaemia in childhood

The cohort of ALL survivors has all been diagnosed and treated for ALL in childhood

Sponsors

Research Unit for General Practice, Aarhus University
CollaboratorOTHER
University of Aarhus
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Years to 18 Years

Inclusion criteria

* B-precursor ALL and T-ALL enrolled in the NOPHO ALL-92, ALL-2000 and ALL-2008 trials. * Treated at one of the four Danish paediatric oncology departments * Age group 1.0-14.9 for the NOPHO ALL-92 and ALL-2000 trials. Age group 1.0-17.9 for the NOPHO ALL-2008 trial. * Completed maintenance therapy in the time period form 01.01.1997 till 31.12.2016

Exclusion criteria

* Children with Down syndrome

Design outcomes

Primary

MeasureTime frameDescription
The yearly contact rate to general practice for ALL survivors and controls1-20 years follow-upAnalysing longitudinal health care data with analysis of both first and recurrent events

Other

MeasureTime frameDescription
The yearly contact rate to secondary healthcare for ALL survivors and controls1-20 years follow-upAnalysing longitudinal health care data with analysis of both first and recurrent events

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026